Quest Diagnostics (DGX) Equity Average (2009 - 2026)

Quest Diagnostics has disclosed Equity Average across 18 years of filings, most recently posting $7.4 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $7.4 billion, up 7.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 billion (up 7.7% YoY), and the FY2025 annual result was $7.0 billion, up 6.29% from the prior year.
• Equity Average came in at $7.4 billion for Q1 2026 at Quest Diagnostics, up from $7.2 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $7.4 billion in Q1 2026 to a low of $6.0 billion in Q1 2023.
• The 5-year median for Equity Average is $6.4 billion (2022), against an average of $6.6 billion.
• Across the five-year window, Equity Average dropped 6.82% in 2023 and advanced 8.4% in 2025, its largest moves.
• Quest Diagnostics' Equity Average stood at $6.1 billion in 2022, then increased by 4.94% to $6.4 billion in 2023, then increased by 6.63% to $6.8 billion in 2024, then climbed by 5.67% to $7.2 billion in 2025, then climbed by 2.83% to $7.4 billion in 2026.
• The last three Equity Average figures came in at $7.4 billion (Q1 2026), $7.2 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.